Beyond insulin: Duopharma’s next act

Wan Amir-Jeffery: The ultimate objective is to generate higher earnings and ensure a good product mix that will contribute positively to our margins.

Duopharma Biotech Bhd’s loss of lead-supplier status in Malaysia’s government human insulin contract has raised questions over whether one of the country’s most established pharmaceutical players is beginning to lose ground in a segment it helped anchor for years.

While Pharmaniaga Bhd’s RM281.67mil insulin contract win changes market optics, it is not projected to fundamentally alter Duopharma’s earnings trajectory.